1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
REGULATORY
CSL’s HAE Drug, Tecentriq Sarcoma Use Clear Panel Review; February Approval Expected
CSL Behring’s hereditary angioedema (HAE) treatment garadacimab and a label expansion for Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) cleared the review of a key health ministry panel on January 30. They are expected to be approved in late February under…
To read the full story
Related Article
- Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025
- CSL’s HAE Drug, Tecentriq Up for Panel Review on Jan. 30; 1st Cases of Expedited Approval
January 17, 2025
- Humira Filed for nr-axSpA in Japan Based on Public Knowledge: AbbVie
September 2, 2024
- Japan to Increase Reimbursement Rounds to 7 Times a Year from 2025
May 16, 2024
- Sanofi Files Sarclisa as 1st-Line Quad Therapy for MM in Japan
May 15, 2024
- Tecentriq Filed for Alveolar Soft Part Sarcoma in Japan: Chugai
March 15, 2024
- Genmab Files Epkinly for Follicular Lymphoma Grade 1-3A in Japan
March 12, 2024
REGULATORY
- Japan to Launch Pilot Project for Adopting Fair Market Value in Clinical Trial Costs
February 28, 2025
- LDP Lawmakers Urge Generic Industry to Ramp Up Production
February 28, 2025
- J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
February 28, 2025
- LDP, Komeito, Ishin Agree to Set Up Consultive Body for Social Security Reform
February 26, 2025
- Coordinate Patent Issues with Originators before Listing: MHLW to Generic Firms
February 26, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…